Article successfully added.

CyFlow™ CD34 Purified

CyFlow™ CD34 Purified
Antibody: Yes
Antigen: CD34
Application: Flow cytometry, Immunocytochemistry, Immunohistochmistry (paraffin-embedded sections), Western blot
Clonality: monoclonal
Clone: 4H11[APG]
Field of Interest: Immunophenotyping
Format/Fluorochrome: Purified
Isotype: IgG1
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: BL106959

For Research Use Only

$120.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
HLDA Workshop HLDA VI—WS Code M MA58 Concentration Unit mg/mL Concentration 1... more
Close menu
CyFlow™ CD34 Purified
HLDA WorkshopHLDA VI—WS Code M MA58
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenPermanent human cell line derived from peripheral leucocytes of a patient suffering from chronic myeloid leukaemia
Background InformationCD34 (Mucosialin) is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G: Receptor‑mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti‑HPCA‑1. J Hematother Stem Cell Res. 2001 Dec; 10(6):863‑71. < PMID: 11798512 > | Dao MA, Arevalo J, Nolta JA: Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood. 2003 Jan 1; 101(1):112‑8. < PMID: 12589631 > | Kish DD, Gorbachev AV, Fairchild RL: CD8+ T cells produce IL‑2, which is required for CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact hypersensitivity responses. J Leukoc Biol. 2005 Sep; 78(3):725‑35. < PMID: 16000396 > | Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Gulati S, Luthra PM: Three‑dimensional structure prediction of the interaction of CD34 with the SH3 domain of Crk‑L. Stem Cells Dev. 2005 Oct; 14(5):470‑7. < PMID: 16305332 > | Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM: Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem Cells Dev. 2006 Jun; 15(3):305‑13. < PMID: 16846369 > | Elknerová K, Lacinová Z, Soucek J, Marinov I, Stöckbauer P: Growth inhibitory effect of the antibody to hematopoietic stem cell antigen CD34 in leukemic cell lines. Neoplasma. 2007; 54(4):311‑20. < PMID: 17822321 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet